文献速递白血病

BCL6维持原代人急性髓系白血病细胞的生存与自我更新

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
PubMed 文献 · Blood · 2021-01-01

该研究探讨BCL6在急性髓系白血病(AML)中的作用,发现AML细胞系和原代样本中BCL6表达水平不一且常较高。BCL6抑制剂可诱导原代AML细胞凋亡、降低集落形成能力,并显著减少小鼠白血病起始能力,而正常造血干细胞功能不受抑制。阿糖胞苷诱导BCL6表达且与耐药相关,BCL6抑制剂联合阿糖胞苷在患者来源异种移植模型中显示增强的抗白血病活性。

要点

  • BCL6在AML细胞中高表达,其水平与BCL6抑制剂敏感性相关(单核分化者除外)。
  • 抑制或敲低BCL6可削弱原代AML细胞的白血病起始能力,但不抑制正常造血干细胞。
  • 阿糖胞苷诱导BCL6表达且与耐药相关,BCL6抑制剂联合阿糖胞苷增强抗白血病活性。

核心结论

  • 药理学抑制BCL6可能通过清除白血病再增殖细胞并提高化疗敏感性,成为AML的新型治疗策略。

研究设计与样本

  • 研究使用AML细胞系、原代AML样本及患者来源异种移植(PDX)小鼠模型,进行基因表达谱分析、凋亡与集落形成实验及白血病起始能力评估。

主要发现

  • BCL6在AML细胞系和原代AML样本中表达水平不一且常较高。
  • BCL6抑制剂处理AML细胞后诱导BCL6抑制的靶基因及DNA损伤检查点相关转录程序,并下调干细胞基因。
  • 原代AML细胞经BCL6抑制剂体外处理可诱导凋亡并降低集落形成能力,且与BCL6表达水平相关。
  • 抑制或敲低BCL6显著减少原代AML细胞在小鼠中的白血病起始能力,提示清除白血病再增殖细胞功能。
  • BCL6敲除或抑制不抑制正常造血干细胞功能;阿糖胞苷进一步诱导BCL6表达,且诱导水平与阿糖胞苷耐药相关。

关键数值与推荐

  • BCL6表达水平较高的AML通常对BCL6抑制剂敏感,但单核分化的AML除外。
  • BCL6抑制剂联合阿糖胞苷在AML PDX模型中显示增强的抗白血病活性。

临床怎么用

  • BCL6表达水平可能作为AML对BCL6抑制剂敏感性的参考指标,但单核分化者可能不敏感。
  • BCL6抑制剂联合阿糖胞苷可能提高AML对化疗的应答,尤其针对BCL6诱导相关的阿糖胞苷耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell lymphoma 6 (BCL6) is a transcription repressor and proto-oncogene that plays a crucial role in the innate and adaptive immune system and lymphoid neoplasms. However, its role in myeloid malignancies remains unclear. Here, we explored the role of BCL6 in acute myeloid leukemia (AML). BCL6 was expressed at variable and often high levels in AML cell lines and primary AML samples. AMLs with higher levels of BCL6 were generally sensitive to treatment with BCL6 inhibitors, with the exception of those with monocytic differentiation. Gene expression profiling of AML cells treated with a BCL6 inhibitor revealed induction of BCL6-repressed target genes and transcriptional programs linked to DNA damage checkpoints and downregulation of stem cell genes. Ex vivo treatment of primary AML cells with BCL6 inhibitors induced apoptosis and decreased colony-forming capacity, which correlated with the levels of BCL6 expression. Importantly, inhibition or knockdown of BCL6 in primary AML cells resulted in a significant reduction of leukemia-initiating capacity in mice, suggesting ablation of leukemia repopulating cell functionality. In contrast, BCL6 knockout or inhibition did not suppress the function of normal hematopoietic stem cells. Treatment with cytarabine further induced BCL6 expression, and the levels of BCL6 induction were correlated with resistance to cytarabine. Treatment of AML patient-derived xenografts with BCL6 inhibitor plus cytarabine suggested enhanced antileukemia activity with this combination. Hence, pharmacologic inhibition of BCL6 might provide a novel therapeutic strategy for ablation of leukemia-repopulating cells and increased responsiveness to chemotherapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kawabata KC, Zong H, Meydan C, et al. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood. 2021. PMID: 32911532. doi:10.1182/blood.2019001745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。